## **Supplementary figures**

## Protocadherin 19 (PCDH19) interacts with paraspeckle protein NONO to co-regulate gene expression with estrogen receptor alpha (ERα)

Duyen H. Pham<sup>1,2</sup>, Chuan Tan<sup>1</sup>, Claire C. Homan<sup>3</sup>, Kristy Kolc<sup>1,2</sup>, Mark Corbett<sup>1,2</sup>, Dale McAninch<sup>3</sup>, Archa Fox<sup>4</sup>, Paul Thomas<sup>3</sup>, Raman Kumar<sup>1,2</sup>, Jozef Gecz<sup>1,2,3,5</sup>

<sup>1</sup> School of Medicine, The University of Adelaide, Adelaide 5000, Australia.

<sup>2</sup> Robinson Research Institute, The University of Adelaide, Adelaide 5006, Australia.


<sup>3</sup> School of Biological Sciences, The University of Adelaide, Adelaide 5000, Australia.

<sup>4</sup> Harry Perkins Institute of Medical Research and Centre for Medical Research, University of


Western Australia, Crawley, Western Australia 6009, Australia.

<sup>5</sup> South Australian Health and Medical Research Institute, Adelaide 5000, Australia.


To whom the correspondence should be addressed at: School of Medicine and The Robinson Research Institute, The University of Adelaide, Adelaide, SA 5000, Australia. Tel: +61 883133245; Fax: +61 881617342; Email: jozef.gecz@adelaide.edu.au **Figure S1.** Spectrum of PCDH19 mutations. Schematic diagram showing spectrum of *PCDH19* mutations: missense (squares), nonsense and CNV (triangles) and those examined in this study (black-squares and a triangle).




**Figure S2.** Schematic diagram of PCDH19 protein. (A) Alignment of C-terminal region of human PCDH19 and mouse Pcdh19. Shaded amino acids represent CM1 and CM2, respectively. (B) Putative nuclear localization signals (NLSs) in the C-terminal region of PCDH19.




В




**Figure S3.** Cellular localization of Myc-PCDH19-FLAG. HeLa cells expressing the doubletagged PCDH19 expression construct with N-terminal Myc and C-terminal FLAG tags (Myc-PCDH19-FLAG) showing predominantly perinuclear and nuclear localization of PCDH19 visualized by staining with anti-Myc (green) and anti-FLAG (red) antibodies. Cell nuclei were visualized by staining with DAPI (blue). Scale bars = 5  $\mu$ m. Images are representative of >200 cells examined.




**Figure S4.** PCDH19, NONO and ER $\alpha$  are present predominantly in the MCF-7 nucleus. Western blot of subcellular fractions from Myc-PCDH19 transfected MCF-7 cells was probed with anti-Myc antibody and endogenous protein with anti-PCDH19 antibody. Endogenous NONO and ER $\alpha$  were also visualised. Histone H3, HSP90 and KCNT1 were used as nuclear, cytoplasmic and membrane markers, respectively.




**Figure S5.** PCDH19 and steroid hormone receptor mRNA levels in a panel of breast cancer cell lines. Steroid hormone receptors ER $\alpha$ , PGR, AR and PCDH19 mRNA was assayed in five cancer and one normal (MCF-10A) breast cell lines by RT-qPCR. MCF-7 cell line has high levels of expression of endogenous PCDH19 and all three steroid hormone receptors (boxed).




**Figure S6.** PCDH19 regulates ERα transcriptional activity. (**A**) MCF-7 cells were transfected with PCDH19 or control siRNA (SCR) for 24h and subsequently transfected with  $3 \times$  ERE TATA luc reporter plasmid. Cells were cultured in charcoal-stripped medium for 16 h and then for 6 h in the presence or absence of 10 nM E2. Data are expressed as relative luciferase activity  $\pm$  SD from three independent experiments. \* p < 0.05 comparing +E2 SCR vs -E2 SCR, \*\*<sup>1</sup> p < 0.01 comparing -E2 SCR vs -E2 PCDH19 siRNA, \*\*<sup>2</sup> p < 0.01 comparing +E2 SCR vs +E2 PCDH19 siRNA cells using Bonferroni adjusted planned comparisons. (**B**) PCDH19 knockdown was confirmed by western blotting the MCF-7 cell extracts with anti-PCDH19 antibody. β-Actin was used as a loading control.




**Figure S7.** ER $\alpha$ -target gene expression is increased in presence of wild-type but is suppressed in presence of mutant Myc-PCDH19. Aldo-keto reducatase 3 (*AKR1C3*), apolipoprotein D (*APOD*), ectodermal neural cortex 1 (*ENC1*) and Oxytoxin receptor (*OXTR*) mRNA was assayed by RT-qPCR in MCF-7 cells transfected with vector, wild-type or Asn557Lys Myc-PCDH19 expression vectors and cultured in the presence of 10 nM E2. The mRNA levels are expressed relative to HPRT. Data are the mean  $\pm$  range from two independent experiments. Each sample was analyzed in triplicate.



**Figure S8.** Wild-type or mutant Myc-PCDH19 does not regulate ER $\alpha$  promoter via ERE in ER $\alpha$ - cells. (A) Luciferase activity was assayed in MCF-7 (ER $\alpha$ +) or MDA-MB-231 (ER $\alpha$ -) cells transfected with reporter containing 3× ERE TATA luc and control, wild-type or mutant Myc-PCDH19 expression vectors. Cells were initially culture in charcoal-stripped medium for 16 h and then for 6 h in the presence or absence of 10 nM E2. Data are expressed as relative luciferase activity ± SD from four independent experiments. \* *p* < 0.05 comparing +E2 WT vs +E2 vector control cells. (B) Levels of Myc-PCDH19 and endogenous-NONO protein were determined by western blotting cell extracts expressing wild-type or mutant Myc-PCDH19 with anti-Myc and anti-NONO antibody, respectively.  $\beta$ -Actin was used as a loading control.



**Figure S9.** PCDH19-mediated ERα transcriptional activity is ERα-dependent. MCF-7 cells were transfected with ERα or control siRNA for 24h and subsequently co-transfected with control or wild-type Myc-PCDH19 plasmids in conjunction with 3× ERE TATA luc reporter plasmid. Cells were cultured in charcoal-stripped medium for 16 h and then in for 6 h in the presence or absence of 10 nM E2. Data are expressed as relative luciferase activity ± SD from three independent experiments. \* *p* < 0.05 comparing +E2 vs –E2 SCR vector control, \*\* *p* < 0.01 comparing –E2 ERα siRNA vector control vs +E2 SCR vector control, \*\*<sup>2</sup> *p* < 0.01 comparing +E2 ERα siRNA vector control, \*\*<sup>3</sup> *p* < 0.01 comparing +E2 SCR WT vs –E2 SCR vector control, \*\*<sup>5</sup> *p* < 0.01 comparing +E2 ERα siRNA weter control, \*\*<sup>3</sup> *p* < 0.01 comparing +E2 SCR WT vs –E2 SCR vector control, \*\*<sup>5</sup> *p* < 0.01 comparing +E2 ERα siRNA weter control, \*\*<sup>3</sup> *p* < 0.01 comparing +E2 SCR WT vs –E2 SCR vector control, \*\*<sup>4</sup> *p* < 0.05 comparing –E2 ERα siRNA WT vs –E2 SCR WT, \*\*<sup>5</sup> *p* < 0.01 comparing +E2 ERα siRNA WT vs +E2 SCR WT cells using Bonferroni adjusted planned comparisons. Western blot of MCF-7 cell extracts expressing wild-type Myc-PCDH19 was probed with anti-Myc antibody. Endogenous ERα was detected using anti-ERα antibody and β-Tubulin was used as a loading control.






Figure S10. Full-length western blots. Original full-length western blots before cropping.